A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation.
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2015
At a glance
- Drugs Everolimus (Primary)
- Indications Transplant rejection
- Focus Adverse reactions
- Acronyms Umbrella
- Sponsors Novartis; Novartis Pharmaceuticals
- 16 Nov 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 18 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 18 Jul 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.